Insight

Myeloma Paper of the Day, May 9th, suggested by Robert Orlowski

Photo of Robert Z. Orlowski from faculty.mdanderson.org

May 10, 2024, 01:01

Myeloma Paper of the Day, May 9th, suggested by Robert Orlowski

Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:

“Myeloma Paper of the Day: University Hospital of Salamanca’s experience with T-cell redirecting therapies in triple-class refractory myeloma suggests OS is better with CAR T approaches vs. bispecifics and CAR T failure best salvaged with bispecific antibodies.”

A research center’s experience of T-cell redirecting therapies in triple-class refractory multiple myeloma

Authors: Borja Puertas, Adolfo Fernández-Sánchez, Elena Alejo, Beatriz Rey-Bua, Ana África Martín-López, Estefaía Pérez López, Miriam Lopez-Parra, Lucia Lopez-Corral, Norma Gutierrez, Ramón García-Sanz, Noemi Puig, Veronica Gonzalez-Calle, and Maria-Victoria Mateos.

Myeloma Paper of the Day

Source: Robert Orlowski/X

Other insights by Robert Orlowski on OncoDaily.

Adolfo Fernández-Sánchez Ana África Martín-López Beatriz Rey-Bua Bispecific antibodies Borja Puertas cancer Elena Alejo Estefaía Pérez López Lucia Lopez-Corral Maria-Victoria Mateos MD Anderson Cancer Center Miriam Lopez-Parra multiple myeloma Myeloma Myeloma Paper of the Day Noemi Puig Norma Gutierrez OncoDaily Oncology Ramón García-Sanz Robert Orlowski University Hospital of Salamanca Veronica Gonzalez-Calle

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage